BTAI (BioXcel Therapeutics) Short Interest


BTAI BioXcel Therapeutics Inc BTAI
14 GF Score
Price $1.31
GF Value $0.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BTAI vs HYEX, CPHI, ZYBT: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Short Interest falls into.


BTAI
14GF Score
BioXcel Therapeutics Inc BTAI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $1.31 is trading 95.2% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.

Key valuation signals for BTAI:

  • Short Interest:
  • GF Value™: $0.67 vs. price of $1.31 (95.2% above fair value)
  • GF Score™: 14/100 with 6 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
14GF Score

Get the complete analysis for BTAI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price
$0.67
GF Value